D. Shames - Concepedia

Author

D. Shames

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

D Shames, D. Shames, D. V. Shames, DENIS V. SHAMES, Denis V. Shames

Publications

229

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Brigham and Women's Hospital University of Colorado Cancer Center City of Hope

About

D. Shames is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	196
2	Health Sciences	1	1	33
3	Public Health	1	1	61
4	Emergency Medicine	1	1	61
5	Immunology	1	1	38

D. Shames

Publications

196

Citations

H-Index

Page 1

	Year	Citations
Myocardial perfusion scintigraphy in patients with mitral valve prolapse: Its advantage over stress electrocardiography in diagnosing associated coronary artery disease and its implications for the etiology of chest pain. Barry M. Massie, E H Botvinick, D. Shames, Circulation Heart FailureRadiologyMitral Valve ProlapseCardiovascular DiseaseConstrictive Pericarditis	1978	61
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study David P. Carbone, J. Lee, Mark G. Kris, Journal of Thoracic Oncology MedicineImmunologyPathologyLcmc3 StudyImmune Checkpoint Inhibitor	2021	38
1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC Mark G. Kris, Jessica M. Grindheim, Jamie E. Chaft, Annals of Oncology Surgical OncologyTumour DnaMedicineMetronomic TherapyPathology	2021	34
Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort Shirish M. Gadgeel, Tony Mok, Solange Peters, Annals of Oncology Treatment-naïve NsclcOncologyClinical EndpointAlk+ CohortClinical Evidence	2019	33
1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations Howard West, Federico Cappuzzo, Martin Reck, Annals of Oncology Keap1 MutationsGenetic DisorderMedicineGeneticsPathology	2020	18
Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc) M. D’Arcangelo, Odd Terje Brustugun, Yang Xiao, Annals of Oncology OncologyProtein ExpressionMedicinePathologyBronchial Neoplasm	2014	12

Page 1